Is Telma-AM banned in India?

Telma-AM combines telmisartan with amlodipine, two blood-pressure drugs, in one tablet. It is Glenmark's product, it is widely prescribed, and it is not banned. Telmisartan + amlodipine is an approved combination that appears in no ban notification.

It is, however, the single most flagged brand in recent CDSCO alerts. The alert for October 2025 listed Telma-AM batch 05241217A among five batches of well-known brands considered potentially spurious, alongside Azithral 500, Noophin and two Chymoral Forte batches; Glenmark said it had not manufactured the batch. The alert for December 2025, published on 21 January 2026, declared seven samples spurious, and three of them were Telma-AM batches, with a Telma 40 batch making a fourth from the same family. The pattern fits what Himachal Pradesh inspectors found in 2022, when a Baddi unit was caught making fake Telma-H under Glenmark's label: the brand is copied because it sells.

A spurious finding in these alerts means the sample was not what its label claimed. In Telma-AM's case that means someone else made the tablets, and there is no way to know from the outside what, if anything, they contain. That is a reason to buy from a licensed pharmacy, keep the bill and compare the batch number with the alerts, and a reason not to trust a strip bought informally because it looks right.

A separate criminal case followed in Gurugram. Medical Dialogues reported on 27 October 2026 that officials seized 178 strips (2,670 tablets) at a distributor, and that Glenmark confirmed in writing that they were counterfeit with forged packaging. At Aushi Immunosciences in Kashipur, Uttarakhand, officials seized two rotary tablet presses, an Alu-Alu blister machine and foil remnants said to match Telma-AM packaging. The alleged supply chain ran through Gurugram and Okhla wholesalers to two entities in Patna. A case was registered on 28 September 2026 under three Drugs and Cosmetics Act provisions. The Additional Sessions Judge granted bail to the two main accused, noting the chargesheet had no FSL report; the district drug controller said the bail would be challenged in the Punjab and Haryana High Court. The allegations are under prosecution and no batch numbers were reported.

It is not a reason to stop a blood-pressure medicine. The licence is unchanged; a doctor can confirm the treatment and a pharmacist can check the pack.